Results from SITS-MOST (Safe Implementation of Thrombolysis in Stroke – Monitoring Study) have confirmed that routine clinical thrombolysis therapy with alteplase (Actilyse), the first and only approved treatment for acute ischaemic stroke, is as safe and effective as previously reported in randomised controlled trials when administered within three hours of onset of a stroke.
The SITS-MOST results show that mortality rates following alteplase treatment were even better in routine practice than had previously been seen in randomised controlled trials (11.3% vs 17.3%). Furthermore, the incidence of symptomatic haemorrhages and of functional independence at three months were comparable to those observed in randomised controlled trials.
SITS-MOST is an open, prospective, observational safety monitoring study for centres practising thrombolysis for acute stroke in Europe. It is the largest stroke registry worldwide, with 6,483 patients recruited to the trial in 285 centres across 14 European countries.